Published in Semin Vasc Med on February 01, 2004
Genetic testing and common disorders in a public health framework: how to assess relevance and possibilities. Background Document to the ESHG recommendations on genetic testing and common disorders. Eur J Hum Genet (2011) 1.57
Heterozygous familial hypercholesterolemia: an underrecognized cause of early cardiovascular disease. CMAJ (2006) 1.30
Familial hypercholesterolaemia in children and adolescents: gaining decades of life by optimizing detection and treatment. Eur Heart J (2015) 1.28
Familial hypercholesterolemia: the lipids or the genes? Nutr Metab (Lond) (2011) 1.04
Founder mutations in the Netherlands: geographical distribution of the most prevalent mutations in the low-density lipoprotein receptor and apolipoprotein B genes. Neth Heart J (2011) 1.00
Genetic testing in the European Union: does economic evaluation matter? Eur J Health Econ (2011) 0.98
Reducing the burden of disease and death from familial hypercholesterolemia: a call to action. Am Heart J (2014) 0.88
Criteria for Diagnosis of Familial Hypercholesterolemia: A Comprehensive Analysis of the Different Guidelines, Appraising their Suitability in the Omani Arab Population. Oman Med J (2014) 0.84
Subjects with molecularly defined familial hypercholesterolemia or familial defective apoB-100 are not being adequately treated. PLoS One (2011) 0.84
Treatment Gaps in Adults With Heterozygous Familial Hypercholesterolemia in the United States: Data From the CASCADE-FH Registry. Circ Cardiovasc Genet (2016) 0.81
Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia. Vasc Health Risk Manag (2010) 0.78
A Case for Inclusion of Genetic Counselors in Cardiac Care. Cardiol Rev (2016) 0.78
Economic evidence on identifying clinically actionable findings with whole-genome sequencing: a scoping review. Genet Med (2015) 0.77
Screening strategies for cardiovascular disease in asymptomatic adults. Prim Care (2014) 0.76
Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med (2008) 43.36
Biological, clinical and population relevance of 95 loci for blood lipids. Nature (2010) 28.21
Effects of torcetrapib in patients at high risk for coronary events. N Engl J Med (2007) 18.78
Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med (2005) 15.18
Large-scale association analysis identifies 13 new susceptibility loci for coronary artery disease. Nat Genet (2011) 13.25
High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA (2005) 12.00
Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA (2011) 8.24
HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med (2007) 6.31
Why are health care interventions delivered over the internet? A systematic review of the published literature. J Med Internet Res (2006) 5.72
Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet (2006) 5.67
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med (2015) 5.59
Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet (2012) 4.63
A randomized trial of rosuvastatin in the prevention of venous thromboembolism. N Engl J Med (2009) 4.46
HDL cholesterol and residual risk of first cardiovascular events after treatment with potent statin therapy: an analysis from the JUPITER trial. Lancet (2010) 4.07
Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. J Am Coll Cardiol (2012) 3.66
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Efficacy and safety of statin therapy in children with familial hypercholesterolemia: a randomized controlled trial. JAMA (2004) 3.55
ACAT inhibition and progression of carotid atherosclerosis in patients with familial hypercholesterolemia: the CAPTIVATE randomized trial. JAMA (2009) 3.33
Novel loci for adiponectin levels and their influence on type 2 diabetes and metabolic traits: a multi-ethnic meta-analysis of 45,891 individuals. PLoS Genet (2012) 3.21
Effect of torcetrapib on glucose, insulin, and hemoglobin A1c in subjects in the Investigation of Lipid Level Management to Understand its Impact in Atherosclerotic Events (ILLUMINATE) trial. Circulation (2011) 3.01
Chylomicronemia with a mutant GPIHBP1 (Q115P) that cannot bind lipoprotein lipase. Arterioscler Thromb Vasc Biol (2009) 2.99
A review on the diagnosis, natural history, and treatment of familial hypercholesterolaemia. Atherosclerosis (2003) 2.97
Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet (2013) 2.92
Genetic variant of the scavenger receptor BI in humans. N Engl J Med (2011) 2.69
Efficacy of statins in familial hypercholesterolaemia: a long term cohort study. BMJ (2008) 2.62
Lipoprotein lipase S447X: a naturally occurring gain-of-function mutation. Arterioscler Thromb Vasc Biol (2006) 2.55
Cost effectiveness analysis of different approaches of screening for familial hypercholesterolaemia. BMJ (2002) 2.55
High-density lipoprotein cholesterol, high-density lipoprotein particle size, and apolipoprotein A-I: significance for cardiovascular risk: the IDEAL and EPIC-Norfolk studies. J Am Coll Cardiol (2008) 2.51
Activation of inflammation and coagulation after infusion of C-reactive protein in humans. Circ Res (2005) 2.46
Association between increased arterial-wall thickness and impairment in ABCA1-driven cholesterol efflux: an observational study. Lancet (2002) 2.39
Automated electronic reminders to facilitate primary cardiovascular disease prevention: randomised controlled trial. Br J Gen Pract (2010) 2.32
Exercise for depression in elderly residents of care homes: a cluster-randomised controlled trial. Lancet (2013) 2.30
Value of low-density lipoprotein particle number and size as predictors of coronary artery disease in apparently healthy men and women: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.29
Effect of intensive lipid lowering with atorvastatin on renal function in patients with coronary heart disease: the Treating to New Targets (TNT) study. Clin J Am Soc Nephrol (2007) 2.26
Role of the apolipoprotein B-apolipoprotein A-I ratio in cardiovascular risk assessment: a case-control analysis in EPIC-Norfolk. Ann Intern Med (2007) 2.26
Serum myeloperoxidase levels are associated with the future risk of coronary artery disease in apparently healthy individuals: the EPIC-Norfolk Prospective Population Study. J Am Coll Cardiol (2007) 2.22
Advising people to take more exercise is ineffective: a randomized controlled trial of physical activity promotion in primary care. Int J Epidemiol (2002) 2.16
Carotid intima-media thickness in children with familial hypercholesterolemia. Circ Res (2013) 2.15
Statin treatment in children with familial hypercholesterolemia: the younger, the better. Circulation (2007) 2.15
Effects of high-dose atorvastatin on cerebrovascular events in patients with stable coronary disease in the TNT (treating to new targets) study. J Am Coll Cardiol (2006) 2.15
Early statin therapy restores endothelial function in children with familial hypercholesterolemia. J Am Coll Cardiol (2002) 2.09
New risk factors for atherosclerosis and patient risk assessment. Circulation (2004) 2.07
Antisense Inhibition of Apolipoprotein C-III in Patients with Hypertriglyceridemia. N Engl J Med (2015) 2.03
High-density lipoprotein particle size and concentration and coronary risk. Ann Intern Med (2009) 2.02
Measurement of arterial wall thickness as a surrogate marker for atherosclerosis. Circulation (2004) 1.98
Loss of endothelial glycocalyx during acute hyperglycemia coincides with endothelial dysfunction and coagulation activation in vivo. Diabetes (2006) 1.97
Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. J Am Coll Cardiol (2009) 1.97
Large-scale gene-centric meta-analysis across 32 studies identifies multiple lipid loci. Am J Hum Genet (2012) 1.96
Comprehensive whole-genome and candidate gene analysis for response to statin therapy in the Treating to New Targets (TNT) cohort. Circ Cardiovasc Genet (2009) 1.95
Family history of premature coronary heart disease and risk prediction in the EPIC-Norfolk prospective population study. Heart (2010) 1.91
Vascular effects and safety of dalcetrapib in patients with or at risk of coronary heart disease: the dal-VESSEL randomized clinical trial. Eur Heart J (2012) 1.91
Cholesteryl ester transfer protein inhibitor torcetrapib and off-target toxicity: a pooled analysis of the rating atherosclerotic disease change by imaging with a new CETP inhibitor (RADIANCE) trials. Circulation (2008) 1.91
Nevirapine and efavirenz elicit different changes in lipid profiles in antiretroviral-therapy-naive patients infected with HIV-1. PLoS Med (2004) 1.89
Efficacy and safety of a novel cholesteryl ester transfer protein inhibitor, JTT-705, in humans: a randomized phase II dose-response study. Circulation (2002) 1.89
Effects of the high-density lipoprotein mimetic agent CER-001 on coronary atherosclerosis in patients with acute coronary syndromes: a randomized trial. Eur Heart J (2014) 1.88
Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J (2011) 1.84
Arterial intima-media thickness in children heterozygous for familial hypercholesterolaemia. Lancet (2004) 1.84
Environmental perceptions and walking in English adults. J Epidemiol Community Health (2004) 1.84
Increased consumption of fruit and vegetables for the primary prevention of cardiovascular diseases. Cochrane Database Syst Rev (2013) 1.82
Replication study of 10 genetic polymorphisms associated with coronary heart disease in a specific high-risk population with familial hypercholesterolemia. Eur Heart J (2008) 1.80
Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J (2012) 1.79
Determinants of residual risk in secondary prevention patients treated with high- versus low-dose statin therapy: the Treating to New Targets (TNT) study. Circulation (2012) 1.76
Genetic variation at the phospholipid transfer protein locus affects its activity and high-density lipoprotein size and is a novel marker of cardiovascular disease susceptibility. Circulation (2010) 1.75
Frequent mutation in the ABCC6 gene (R1141X) is associated with a strong increase in the prevalence of coronary artery disease. Circulation (2002) 1.74
Endothelial glycocalyx damage coincides with microalbuminuria in type 1 diabetes. Diabetes (2006) 1.74
Intensive lipid lowering with atorvastatin in patients with coronary heart disease and chronic kidney disease: the TNT (Treating to New Targets) study. J Am Coll Cardiol (2008) 1.73
Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol (2005) 1.73
Seven lipoprotein lipase gene polymorphisms, lipid fractions, and coronary disease: a HuGE association review and meta-analysis. Am J Epidemiol (2008) 1.71
Efficacy and safety of a novel oral inducer of apolipoprotein a-I synthesis in statin-treated patients with stable coronary artery disease a randomized controlled trial. J Am Coll Cardiol (2011) 1.71
Diagnosing familial hypercholesterolaemia: the relevance of genetic testing. Eur Heart J (2006) 1.68
Predictive value of mild, residual descending aortic narrowing for blood pressure and vascular damage in patients after repair of aortic coarctation. Eur Heart J (2004) 1.67
Molecular basis of autosomal dominant hypercholesterolemia: assessment in a large cohort of hypercholesterolemic children. Circulation (2011) 1.65
Thrombospondin-2 polymorphism is associated with a reduced risk of premature myocardial infarction. Arterioscler Thromb Vasc Biol (2002) 1.62
An integrated evaluation of endothelial constitutive nitric oxide synthase polymorphisms and coronary artery disease in men. Clin Sci (Lond) (2004) 1.61
Chylomicronemia with low postheparin lipoprotein lipase levels in the setting of GPIHBP1 defects. Circ Cardiovasc Genet (2010) 1.60
Building capacity for public and population health research in Africa: the consortium for advanced research training in Africa (CARTA) model. Glob Health Action (2010) 1.59
A novel apoA-I mutation (L178P) leads to endothelial dysfunction, increased arterial wall thickness, and premature coronary artery disease. J Am Coll Cardiol (2004) 1.58
C-reactive protein and cardiovascular risk: more fuel to the fire. Lancet (2009) 1.57
Treatment of periodontitis improves the atherosclerotic profile: a systematic review and meta-analysis. J Clin Periodontol (2013) 1.57
Health inequalities among older men and women in Africa and Asia: evidence from eight Health and Demographic Surveillance System sites in the INDEPTH WHO-SAGE Study. Glob Health Action (2010) 1.54
Effect of aliskiren on progression of coronary disease in patients with prehypertension: the AQUARIUS randomized clinical trial. JAMA (2013) 1.54
The endothelial glycocalyx: a potential barrier between health and vascular disease. Curr Opin Lipidol (2005) 1.53
Efflux and atherosclerosis: the clinical and biochemical impact of variations in the ABCA1 gene. Arterioscler Thromb Vasc Biol (2003) 1.53
Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation (2014) 1.53
Exome sequencing in suspected monogenic dyslipidemias. Circ Cardiovasc Genet (2015) 1.51
The PCSK9 decade. J Lipid Res (2012) 1.50
A review of CETP and its relation to atherosclerosis. J Lipid Res (2004) 1.50
Carriers of lecithin cholesterol acyltransferase gene mutations have accelerated atherogenesis as assessed by carotid 3.0-T magnetic resonance imaging [corrected]. J Am Coll Cardiol (2011) 1.50
Identifying individuals for primary cardiovascular disease prevention in UK general practice: priorities and resource implications. Br J Gen Pract (2008) 1.49
Follow-up of children diagnosed with familial hypercholesterolemia in a national genetic screening program. J Pediatr (2012) 1.46
Asymptomatic individuals with a positive family history for premature coronary artery disease and elevated coronary calcium scores benefit from statin treatment: a post hoc analysis from the St. Francis Heart Study. JACC Cardiovasc Imaging (2012) 1.46